未登录

R

Robert C. Penland

clinical pharmacology

H指数:14

被引数:1,180

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eosinophilic Depletion with Benralizumab; Mepolizumab; and Depemokimab: A Modeling Study

嗜酸性粒细胞耗竭与Benralizumab、Mepolizumab和Depemokimab：一项建模研究

Journal of Asthma and Allergy

IF3

2026-05-190

OAAI

Population Pharmacokinetics and Exposure–Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma

中国成人、青少年和儿科重度嗜酸性粒细胞哮喘患者中苯那利单抗的群体药代动力学和暴露-反应分析

Clinical Pharmacokinetics

IF4

2025-06-230

OA

Potassium homeostasis and therapeutic intervention with sodium zirconium cyclosilicate: A model-informed drug development case study

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-12-041

OAAI

Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus

射血分数降低的心力衰竭患者和2型糖尿病患者之间的达格列净药代动力学相似

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-11-200

PRE

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-03-161

OAAI

Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials

DIABETES OBESITY & METABOLISM

IF5.7

2021-02-026

PREAI

A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2021-01-256

PRE

Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2020-10-019

OAAI

Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: Apost hocanalysis of theEXSCELtrial

DIABETES OBESITY & METABOLISM

IF5.7

2020-09-1522

OAAI

Once-Weekly Exenatide Effects on EGFR Slope and UACR as a Function of Baseline UACR: An EXSCEL Trial Post Hoc Analysis

IF7.5

2020-06-010

PRE

Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-03-0631

OAAI

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL

DIABETES OBESITY & METABOLISM

IF5.7

2020-02-0312

OAAI

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

CARDIOVASCULAR DIABETOLOGY

IF10.6

2019-10-2254

OAAI

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors

DIABETES OBESITY & METABOLISM

IF5.7

2019-09-0929

PREAI

Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2019-06-1144

OAAI

Effect of Open-Label SGLT2 Inhibitor Treatment When Combined with Exenatide on Cardiovascular and Renal Outcomes in EXSCEL

IF7.5

2019-06-011

PRE

Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus

DIABETES OBESITY & METABOLISM

IF5.7

2018-12-165

OAAI

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL

IF16.6

2018-12-0627

OAAI

Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group

IF7.5

2018-07-011

PRE

Dapagliflozin Exposure Response in Japanese vs. Non-Japanese Patients with Type 1 Diabetes

IF7.5

2018-07-010

PRE